TECHBio-Techne
$72.79+20% 1Y
$72.79
$43.2252 weeks$72.79
Latest close: a new 52-week highNov 6, 2026what changed →
What has happened
TECH in its own filings
TECH's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
384
Events found in the filings · across 1,280 filings · the record starts in 1995
- Hard flags
- 1
Hard flags · all historical, the latest in 2017
- Most recent filing
- Nov 4, 2026
Most recent filing · Form 8-K
- Record starts
- May 10, 1995
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Late periodic report2 occurrences
- 2017-08-29
- SEC comment-letter activity32 occurrences
- 2023-02-16
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Shareholder vote results
On September 23, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), held a special meeting of shareholders (the “Special Meeting”) to consider and vote on certain proposals related to the Agreement and Plan of Merger, dated as of June 25, 2026 (as it may be amended from time to time in accordance …
Form 8-K on sec.gov ↗ - Other event
As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Merck KGaA, Darmstadt, Germany”) and EMD Holdings NewCo …
Form 8-K on sec.gov ↗
Earlier reports (7)›
- Earnings release
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results.
The press release on sec.gov ↗ - Material agreement entered
On June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Parent”), and EMD Holdings NewCo, Inc., a Minnesota corporation and a wholly-owned …
Form 8-K on sec.gov ↗ - Regulation FD disclosure
Strengthening Leadership Position in Fast-Growing Life Sciences Markets.
The press release on sec.gov ↗ - Earnings release
Bio-Techne Releases Third Quarter Fiscal 2026 Results.
The press release on sec.gov ↗ - Director or officer change
Officer Transition On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth …
Form 8-K on sec.gov ↗ - Earnings release
Bio-Techne Releases Second Quarter Fiscal 2026 Results.
The press release on sec.gov ↗ - Earnings release
A quorum was present at the Annual Meeting with 140,827,559 shares represented personally or by proxy, which represents approximately 90.45% of the outstanding shares of the Company's common stock.
Form 8-K on sec.gov ↗
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screensStocks with more cash than debt
Biotechnology
The closest names by size in the same industry